[go: up one dir, main page]

DK3662932T3 - Anti-cgrp-sammensætninger og anvendelse deraf - Google Patents

Anti-cgrp-sammensætninger og anvendelse deraf Download PDF

Info

Publication number
DK3662932T3
DK3662932T3 DK19215303.9T DK19215303T DK3662932T3 DK 3662932 T3 DK3662932 T3 DK 3662932T3 DK 19215303 T DK19215303 T DK 19215303T DK 3662932 T3 DK3662932 T3 DK 3662932T3
Authority
DK
Denmark
Prior art keywords
application
cgrp compositions
cgrp
compositions
Prior art date
Application number
DK19215303.9T
Other languages
English (en)
Inventor
Benjamin H Dutzar
Jens J Billgren
John A Latham
Danielle M Mitchell
Patricia Dianne Mcneill
Nicole M Janson
Maria-Cristina Loomis
Brian Robert Kovacevich
Leon F Garcia-Martinez
Katie Olson
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3662932(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK3662932T3 publication Critical patent/DK3662932T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK19215303.9T 2011-05-20 2012-05-21 Anti-cgrp-sammensætninger og anvendelse deraf DK3662932T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161488660P 2011-05-20 2011-05-20
EP18203518.8A EP3495392B1 (en) 2011-05-20 2012-05-21 Anti-cgrp compositions and use thereof

Publications (1)

Publication Number Publication Date
DK3662932T3 true DK3662932T3 (da) 2021-05-17

Family

ID=47175055

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18203518.8T DK3495392T3 (da) 2011-05-20 2012-05-21 Anti-cgrp-sammensætninger og anvendelse deraf
DK19215303.9T DK3662932T3 (da) 2011-05-20 2012-05-21 Anti-cgrp-sammensætninger og anvendelse deraf
DK12789693.4T DK2710039T3 (da) 2011-05-20 2012-05-21 Anti-cgrp-sammensætninger og anvendelse deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK18203518.8T DK3495392T3 (da) 2011-05-20 2012-05-21 Anti-cgrp-sammensætninger og anvendelse deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12789693.4T DK2710039T3 (da) 2011-05-20 2012-05-21 Anti-cgrp-sammensætninger og anvendelse deraf

Country Status (37)

Country Link
US (10) US9745373B2 (da)
EP (5) EP3662932B1 (da)
JP (3) JP6282584B2 (da)
KR (1) KR102128627B1 (da)
CN (5) CN107586338B (da)
AP (1) AP2013007259A0 (da)
AR (3) AR086516A1 (da)
AU (3) AU2012258966C1 (da)
BR (2) BR122022012930B1 (da)
CA (3) CA3080000A1 (da)
CL (3) CL2013003336A1 (da)
CO (1) CO6870005A2 (da)
CY (2) CY1124209T1 (da)
DK (3) DK3495392T3 (da)
EA (3) EA039905B1 (da)
ES (3) ES2873837T3 (da)
FR (1) FR22C1032I2 (da)
HR (3) HRP20190640T1 (da)
HU (4) HUE055505T2 (da)
IL (4) IL229431B (da)
LT (4) LT2710039T (da)
MX (3) MX370749B (da)
NL (1) NL301181I2 (da)
NO (1) NO2022029I1 (da)
NZ (1) NZ733060A (da)
PE (2) PE20141787A1 (da)
PH (2) PH12013502405B1 (da)
PL (3) PL3495392T3 (da)
PT (3) PT2710039T (da)
RS (3) RS62306B1 (da)
SG (2) SG10201604040PA (da)
SI (3) SI3662932T1 (da)
SM (3) SMT202100274T1 (da)
TR (1) TR201904088T4 (da)
TW (4) TWI685505B (da)
WO (1) WO2012162243A2 (da)
ZA (1) ZA201308637B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20115333B (en) 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
CN101959528A (zh) 2008-03-04 2011-01-26 辉瑞有限公司 治疗慢性疼痛的方法
EP3662932B1 (en) * 2011-05-20 2021-04-07 H. Lundbeck A/S Anti-cgrp compositions and use thereof
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
HUE069556T2 (hu) * 2011-05-20 2025-03-28 H Lundbeck As Anti-CGRP antitestek és antitestfragmensek alkalmazása fotofóbia vagy fotoaverzió megelõzésére vagy gátlására erre rászoruló alanyokban, különösen migrénben szenvedõkben
TWI670279B (zh) 2013-03-15 2019-09-01 美商艾爾德生物製藥股份有限公司 抗體純化及純度監測
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
ES2911690T3 (es) * 2013-07-03 2022-05-20 H Lundbeck As Regulación del metabolismo de la glucosa mediante anticuerpos anti-CGRP
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3283169A4 (en) 2015-04-16 2019-03-20 Alder Biopharmaceuticals, Inc. USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF FOR THE TREATMENT, PREVENTION OR INHIBITION OF PHOTOPHOBY
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
US20170088612A1 (en) * 2015-09-24 2017-03-30 Teva Pharmaceuticals International Gmbh Preventing, treating, and reducing (persistent) post-traumatic headache
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
CN108473567A (zh) * 2016-01-28 2018-08-31 伊莱利利公司 Cgrp抗体及其用途
CN108601833B (zh) 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
MX2019003338A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento de cefalea en racimos.
WO2018160897A1 (en) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Preventing post-ictal headaches
AU2018254530A1 (en) * 2017-04-19 2019-10-31 John Mansell Compositions and methods for treating pain disorders
CA3087951A1 (en) 2018-01-12 2019-07-18 Amgen Inc. Pac1 antibodies and uses thereof
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
JP2021518748A (ja) * 2018-02-23 2021-08-05 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
WO2019231800A1 (en) * 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
US10899826B1 (en) * 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (en) * 2018-12-26 2020-07-01 Life Length S.L. Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
SG11202106878XA (en) * 2019-01-08 2021-07-29 H Lundbeck As Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies
JP7219512B2 (ja) * 2019-02-28 2023-02-08 エイチエルビー サイエンス インコーポレイテッド 抗菌活性を有するポリペプチド、これを含む敗血症の予防または治療用組成物、および抗菌用組成物
MX2021013426A (es) * 2019-05-02 2021-12-10 H Lundbeck As Tratamiento de la cefalea usando anticuerpos anti-cgrp.
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
CA3229059A1 (en) 2021-08-27 2023-03-02 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3662333A (en) 1970-09-08 1972-05-09 Bendix Corp Hydraulic accumulator charge detector and indicating system
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5123197A (ja) 1974-08-21 1976-02-24 Hitachi Ltd Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0134631B1 (en) * 1983-06-15 1991-04-03 Celltech Limited Peptides, pharmaceutical compositions, genes, vectors, host organisms, processes for their production and diagnostic reagents
JPS62129297A (ja) 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5364841A (en) 1988-01-11 1994-11-15 Amylin Pharmaceuticals, Inc. Treatment of obesity and essential hypertension and related disorders
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
FR2669336B1 (fr) 1990-11-20 1993-01-22 Adir Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) * 1992-08-19 1994-02-03 Henning Berlin Gmbh Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994021293A1 (en) 1993-03-19 1994-09-29 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5475995A (en) 1994-05-16 1995-12-19 Livingston; George G. Truck spare tire locking rod
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
ES2251723T3 (es) 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
AU7953194A (en) 1994-08-16 1996-03-07 Human Genome Sciences, Inc. Calcitonin receptor
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en) 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
WO1997009046A1 (en) 1995-09-05 1997-03-13 Smithkline Beecham Corporation Compounds and methods
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
WO1998009630A1 (en) 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
EA004037B1 (ru) 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Модифицированные аминокислоты и лекарственное средство на их основе
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
WO2000018764A1 (en) 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
US20010036647A1 (en) 1998-10-22 2001-11-01 Prabhakara V. Choudary Functionally assembled antigen-specific intact recombinant antibody and a method for production thereof
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
CN101543507A (zh) 1999-09-25 2009-09-30 衣阿华大学研究基金会 免疫刺激性核酸
CA2401652A1 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en) 2001-08-17 2003-09-25 Boehringer Ingelheim Pharma Kg Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
CN1617737A (zh) 2001-11-26 2005-05-18 普罗特米克斯公司 用于使哺乳动物组织中的脂质水平正常化的组合物和方法
WO2003085089A2 (en) 2002-03-29 2003-10-16 Schering Corporation Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
EP1501929B1 (de) 2002-05-06 2013-03-27 Noxxon Pharma AG Cgrp bindende nukleinsäuren
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
NZ537315A (en) 2002-06-05 2006-04-28 Bristol Myers Squibb Co Calcitonin gene related peptide receptor antagonists
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
BR0313388A (pt) 2002-08-12 2005-07-05 Birkir Sveinsson Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CA2508375C (en) 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
ES2382918T3 (es) 2002-12-24 2012-06-14 Rinat Neuroscience Corp. Anticuerpos anti-NGF y procedimientos que usan los mismos
ATE516803T1 (de) 2003-03-14 2011-08-15 Merck Sharp & Dohme Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
JP4690313B2 (ja) 2003-03-14 2011-06-01 メルク・シャープ・エンド・ドーム・コーポレイション カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
US7205293B2 (en) 2003-03-14 2007-04-17 Merck & Co., Inc. Benodiazepine spirohydantoin CGRP receptor antagonists
AU2004221891B2 (en) 2003-03-14 2009-11-19 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin CGRP receptor antagonists
WO2004082605A2 (en) 2003-03-14 2004-09-30 Merck & Co. Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
DE602004027021D1 (de) 2003-04-15 2010-06-17 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
AU2004259675A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine CGRP receptor antagonists
EP1678314B1 (en) * 2003-10-22 2012-09-05 Keck Graduate Institute Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US20080070239A1 (en) 2003-10-29 2008-03-20 University Of Rochester Detection of neureopeptides associated with pelvic pain disorders and uses thereof
WO2005070444A2 (en) 2004-01-13 2005-08-04 Vasogenix Pharmaceuticals, Inc. Methods for treating acute myocardial infarction by calcitonin gene related peptide and compositions containing the same
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
US20100144767A1 (en) 2005-08-25 2010-06-10 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
GEP20115333B (en) * 2005-11-14 2011-11-25 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin generelated peptide and using same
US20070108378A1 (en) 2005-11-14 2007-05-17 Toru Terabayashi High pressure optical cell for a downhole optical fluid analyzer
WO2007061676A2 (en) 2005-11-18 2007-05-31 Merck & Co., Inc. Spirohydantoin aryl cgrp receptor antagonists
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US9074352B2 (en) 2006-03-27 2015-07-07 John R. Ramun Universal control scheme for mobile hydraulic equipment and method for achieving the same
DK2021463T3 (da) 2006-05-19 2017-01-16 Alder Biopharmaceuticals Inc Dyrkningsfremgangsmåde til at opnå en klonet population af antigen-specifikke B-celler
PE20080153A1 (es) 2006-06-08 2008-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende un antagonista del peptido relacionado con el gen calcitonina (cgrp)
EP2049532B1 (en) 2006-07-21 2010-06-02 Vertex Pharmaceuticals, Inc. Cgrp receptor antagonists
US8075902B2 (en) * 2007-01-03 2011-12-13 Michael Powell Diagnosis and treatment of cancer related to human dormancy
AU2008254578B2 (en) 2007-05-21 2013-06-06 Alderbio Holdings Llc Novel rabbit antibody humanization methods and humanized rabbit antibodies
LT3187506T (lt) 2007-05-21 2019-04-25 Alderbio Holdings Llc Il-6 antikūnai ir jų panaudojimas
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
GB0725103D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Novel compounds
KR101304085B1 (ko) 2008-03-04 2013-09-05 라브리스 바이올로직스 인코포레이티드 염증성 통증의 치료 방법
CN101959528A (zh) 2008-03-04 2011-01-26 辉瑞有限公司 治疗慢性疼痛的方法
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP3165236B1 (en) 2009-08-28 2022-03-16 Teva Pharmaceuticals International GmbH Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US11214610B2 (en) * 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
HUE069556T2 (hu) 2011-05-20 2025-03-28 H Lundbeck As Anti-CGRP antitestek és antitestfragmensek alkalmazása fotofóbia vagy fotoaverzió megelõzésére vagy gátlására erre rászoruló alanyokban, különösen migrénben szenvedõkben
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
EP3662932B1 (en) * 2011-05-20 2021-04-07 H. Lundbeck A/S Anti-cgrp compositions and use thereof
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US20170088612A1 (en) 2015-09-24 2017-03-30 Teva Pharmaceuticals International Gmbh Preventing, treating, and reducing (persistent) post-traumatic headache
WO2018160897A1 (en) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Preventing post-ictal headaches
US11752099B2 (en) * 2017-03-27 2023-09-12 W. L. Gore & Associates, Inc. Injectable and biodegradable polymer formulations for controlled release of bioactive agents
US11400136B2 (en) * 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
SG11202106878XA (en) 2019-01-08 2021-07-29 H Lundbeck As Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies

Also Published As

Publication number Publication date
TWI685505B (zh) 2020-02-21
JP2014517699A (ja) 2014-07-24
US10533048B2 (en) 2020-01-14
US20240174738A1 (en) 2024-05-30
EP2710039A4 (en) 2014-11-19
TW201300419A (zh) 2013-01-01
TW202033559A (zh) 2020-09-16
EP4115905A1 (en) 2023-01-11
LT3495392T (lt) 2021-09-27
US10214582B2 (en) 2019-02-26
PT3495392T (pt) 2021-09-22
CN108373502B (zh) 2022-03-22
SI3495392T1 (sl) 2021-11-30
EA039905B1 (ru) 2022-03-25
BR112013029932A2 (pt) 2017-01-31
WO2012162243A2 (en) 2012-11-29
US20120294797A1 (en) 2012-11-22
PH12018500521A1 (en) 2019-04-15
EP3662932B1 (en) 2021-04-07
IL270382B (en) 2020-11-30
US20180215816A1 (en) 2018-08-02
AU2019226231B2 (en) 2021-06-03
EP3875115A1 (en) 2021-09-08
IL261927A (en) 2018-10-31
MX2019008185A (es) 2019-09-09
EP3495392A1 (en) 2019-06-12
WO2012162243A3 (en) 2013-01-17
CA2836649A1 (en) 2012-11-29
JP2019150044A (ja) 2019-09-12
IL261927B (en) 2019-11-28
MX370749B (es) 2019-12-20
SI2710039T1 (sl) 2019-05-31
PE20141787A1 (es) 2014-12-07
EA031065B1 (ru) 2018-11-30
SMT201900293T1 (it) 2019-07-11
US20180215815A1 (en) 2018-08-02
PE20180502A1 (es) 2018-03-09
IL229431B (en) 2018-10-31
PL2710039T3 (pl) 2019-07-31
CN108424452A (zh) 2018-08-21
NZ717570A (en) 2018-09-28
LT3662932T (lt) 2021-06-10
AU2019226231A1 (en) 2019-09-26
EP3495392B1 (en) 2021-08-18
US20190092842A1 (en) 2019-03-28
MX2013013535A (es) 2015-08-20
PL3662932T3 (pl) 2021-09-06
TR201904088T4 (tr) 2019-05-21
CL2017001379A1 (es) 2017-12-29
CL2018001452A1 (es) 2018-08-10
SMT202100274T1 (it) 2021-07-12
CN107586338A (zh) 2018-01-16
US20180215814A1 (en) 2018-08-02
CN107586338B (zh) 2021-09-17
EA201891284A1 (ru) 2018-11-30
EP2710039B1 (en) 2019-01-09
NL301181I2 (nl) 2022-11-24
US20190211085A1 (en) 2019-07-11
CN108424452B (zh) 2021-08-03
IL268464B (en) 2020-10-29
AU2012258966C1 (en) 2022-02-03
LTPA2022511I1 (da) 2022-07-11
NL301181I1 (da) 2022-06-15
EA201301295A1 (ru) 2014-04-30
AR123876A2 (es) 2023-01-18
KR20140042819A (ko) 2014-04-07
PH12013502405B1 (en) 2018-11-07
EP2710039A2 (en) 2014-03-26
PT3662932T (pt) 2021-05-14
HRP20210777T1 (hr) 2021-06-25
ES2715001T3 (es) 2019-05-31
EP3662932A1 (en) 2020-06-10
US10189895B2 (en) 2019-01-29
ZA201308637B (en) 2022-11-30
NZ618637A (en) 2016-03-31
PL3495392T3 (pl) 2021-12-13
CN108373502A (zh) 2018-08-07
AR086516A1 (es) 2013-12-18
HRP20190640T1 (hr) 2019-05-31
US20180215813A1 (en) 2018-08-02
TWI719869B (zh) 2021-02-21
FR22C1032I1 (fr) 2022-09-09
DK3495392T3 (da) 2021-09-13
RS61793B1 (sr) 2021-06-30
CA3079978A1 (en) 2012-11-29
ES2893073T3 (es) 2022-02-07
NO2022029I1 (no) 2022-07-08
SI3662932T1 (sl) 2021-08-31
TW201811835A (zh) 2018-04-01
PT2710039T (pt) 2019-04-23
US11111289B2 (en) 2021-09-07
PH12013502405A1 (en) 2014-02-10
LT2710039T (lt) 2019-04-25
RS62306B1 (sr) 2021-09-30
HRP20211395T1 (hr) 2021-12-10
AU2012258966B2 (en) 2017-03-09
JP2018038391A (ja) 2018-03-15
US10066009B2 (en) 2018-09-04
HUE055505T2 (hu) 2021-11-29
IL229431A0 (en) 2014-01-30
CN107602700A (zh) 2018-01-19
EA201592042A1 (ru) 2016-03-31
JP6282584B2 (ja) 2018-02-21
US20170174754A1 (en) 2017-06-22
AP2013007259A0 (en) 2013-11-30
US10208112B2 (en) 2019-02-19
FR22C1032I2 (fr) 2023-06-02
KR102128627B1 (ko) 2020-06-30
CN103748111A (zh) 2014-04-23
DK2710039T3 (da) 2019-04-01
US20210047391A1 (en) 2021-02-18
AR118605A2 (es) 2021-10-20
CL2013003336A1 (es) 2014-06-06
CO6870005A2 (es) 2014-02-20
CA2836649C (en) 2020-06-23
CY1124209T1 (el) 2022-05-27
BR122022012930B1 (pt) 2023-10-10
HUS2200031I1 (hu) 2022-07-28
JP6527563B2 (ja) 2019-06-05
AU2017203890B2 (en) 2019-06-06
CN103748111B (zh) 2018-04-27
AU2017203890A1 (en) 2017-06-29
RS58621B1 (sr) 2019-05-31
CY1124515T1 (el) 2022-07-22
HUE054437T2 (hu) 2021-09-28
CA3080000A1 (en) 2012-11-29
ES2873837T3 (es) 2021-11-04
TW201936642A (zh) 2019-09-16
US10179809B2 (en) 2019-01-15
JP6952736B2 (ja) 2021-10-20
NZ733060A (en) 2022-08-26
SG10201604040PA (en) 2016-07-28
SMT202100526T1 (it) 2021-11-12
TWI692485B (zh) 2020-05-01
MX2019015745A (es) 2020-02-13
US9745373B2 (en) 2017-08-29
IL268464A (en) 2019-09-26
CN107602700B (zh) 2021-12-17
TWI646111B (zh) 2019-01-01
SG194938A1 (en) 2013-12-30
HUE044062T2 (hu) 2019-09-30

Similar Documents

Publication Publication Date Title
CY2022019I1 (el) Συνθεσεις αντι-cgrp και χρησεις αυτων
HUS2200031I1 (hu) Anti-CGRP készítmények és alkalmazásuk
DK3366143T3 (da) Probiotiske sammensætninger og fremgangsmåder
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
DK2763665T3 (da) Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
BR112013023776A2 (pt) composição e abertura vedada com selante
BR112014010450A2 (pt) composição e método
EP2762504A4 (en) WATER- AND OIL-REPELLING COMPOSITION
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf
BR112014010860A2 (pt) composição e método
DK2672837T4 (da) Ernæringssammensætning og anvendelser deraf
BR112012029669A2 (pt) composição e método
BR112014007779A2 (pt) método e composição
EP2749168A4 (en) PLASTERIC COMPOSITION AND ITS USE
BR112013019707A2 (pt) métodos e composições antinematóides
BR112013008812A2 (pt) composição e método
BR112013013441A2 (pt) composição de adesivo-engomadura e métodos relacionados